This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Results of the Yale Tardive Dyskinesia Study

Hal Morgenstern, PhD; William M. Glazer, MD

Arch Gen Psychiatry. 1993;50(9):723-733.

Abstract
Objectives
To describe the incidence of tardive dyskinesia (TD) in the Yale TD Study and to identify demographic, treatment, and clinical risk factors for TD occurrence.

Design
An ongoing prospective cohort study in which subjects have been examined every 6 months since 1985.

Setting
The outpatient division of the Connecticut Mental Health Center in New Haven.

Subjects
Three hundred ninety-eight adult outpatients who had been maintained with neuroleptics for 3 months to 33 years at intake and who were free of persistent TD at intake with no history of persistent TD movements.

Outcome Measure
New cases of persistent TD were defined as the presence of mild or more severe dyskinetic movements at two successive follow-up visits, using the Abnormal Involuntary Movement Scale.

Results
As of July 1, 1990, there were 62 new persistent cases of TD, yielding an average incidence rate of 0.053 per year and a 5-year risk of 20%. The TD rate was positively affected by age, being nonwhite, and neuroleptic dose, and it was inversely affected by years of previous exposure. Little or no effects were found for age at first neuroleptic exposure, type of neuroleptic, use of other psychiatric medications, and psychiatric diagnosis.

Conclusions
For outpatients maintained for many years with neuropleptics, dose should be minimized to reduce the risk of TD. This strategy does not appear to be negated by prescribing frequent changes in dosage. Although the TD rate is greatest during the first 5 years of neuroleptic treatment, new persistent cases continue to occur many years after first exposure.

Author Affiliations
From the Departments of Epidemiology, UCLA School of Public Health, Los Angeles, Calif (Dr Morgenstern); and Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven (Dr Glazer).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX
Wilffert et al.
J Psychopharmacol 2009;23:652-659.
ABSTRACT  

Predictors of Abnormal Involuntary Movement in an African Schizophrenia Population
Niehaus et al.
J. Neuropsychiatry Clin. Neurosi. 2008;20:317-326.
ABSTRACT | FULL TEXT  

Adverse effects of antipsychotics as outcome measures
Hamer and Haddad
Br. J. Psychiatry 2007;191:s64-s70.
ABSTRACT | FULL TEXT  

Cross-Cultural Psychopharmacology: A Current Clinical Perspective
Focus 2006;4:62.
 

Gender Differences in the Prescribing of Antipsychotic Drugs
Focus 2006;4:115.
 

Rational pharmacotherapy in early psychosis
REMINGTON
Br. J. Psychiatry 2005;187:s77-s84.
ABSTRACT | FULL TEXT  

Psychopharmacology: Cross-Cultural Psychopharmacology: A Current Clinical Perspective
Pi and Simpson
Psychiatr. Serv. 2005;56:31-33.
FULL TEXT  

Gender Differences in the Prescribing of Antipsychotic Drugs
Seeman
Am. J. Psychiatry 2004;161:1324-1333.
ABSTRACT | FULL TEXT  

Olanzapine vs Haloperidol for Treatment of Schizophrenia--Reply
Rosenheck et al.
JAMA 2004;291:1065-1066.
FULL TEXT  

Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies
Correll et al.
Am. J. Psychiatry 2004;161:414-425.
ABSTRACT | FULL TEXT  

Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials
Chakos et al.
Focus 2004;2:111-121.
ABSTRACT | FULL TEXT  

Best Practices: Racial and Ethnic Effects on Antipsychotic Prescribing Practices in a Community Mental Health Center
Woods et al.
Psychiatr. Serv. 2003;54:177-179.
FULL TEXT  

Outpatient Prescriptions for Atypical Antipsychotics for African Americans, Hispanics, and Whites in the United States
Daumit et al.
Arch Gen Psychiatry 2003;60:121-128.
ABSTRACT | FULL TEXT  

Melatonin Treatment for Tardive Dyskinesia: A Double-blind, Placebo-Controlled, Crossover Study
Shamir et al.
Arch Gen Psychiatry 2001;58:1049-1052.
ABSTRACT | FULL TEXT  

Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials
Chakos et al.
Am. J. Psychiatry 2001;158:518-526.
ABSTRACT | FULL TEXT  

Low dose typical antipsychotics - a brief evaluation
Taylor
The Psychiatrist 2000;24:465-468.
FULL TEXT  

Risperidone Treatment of Behavioral Disturbances in Outpatients With Dementia
Irizarry et al.
J. Neuropsychiatry Clin. Neurosi. 1999;11:336-342.
ABSTRACT | FULL TEXT  

Prospective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors
Woerner et al.
Am. J. Psychiatry 1998;155:1521-1528.
ABSTRACT | FULL TEXT  

Spontaneous Abnormal Involuntary Movements in First-Episode Schizophrenia and Schizophreniform Disorder: Baseline Rate in a Group of Patients From an Irish Catchment Area
Gervin et al.
Am. J. Psychiatry 1998;155:1202-1206.
ABSTRACT | FULL TEXT  

Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated With Tardive Dyskinesia
Tsai et al.
Am. J. Psychiatry 1998;155:1207-1213.
ABSTRACT | FULL TEXT  

Marked Reduction of Tardive Dyskinesia With Olanzapine
Littrell et al.
Arch Gen Psychiatry 1998;55:279-280.
FULL TEXT  

Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia
Chakos et al.
Arch Gen Psychiatry 1996;53:313-319.
ABSTRACT  

Risk of Tardive Dyskinesia in Older Patients: A Prospective Longitudinal Study of 266 Outpatients
Jeste et al.
Arch Gen Psychiatry 1995;52:756-765.
ABSTRACT